Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

NCT06954090 on ClinicalTrials.gov · last registry update 2025-12-22

50 participants. Due to report 30 November 2026, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Proteomic feasibility. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for diabetic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: ENROLLING_BY_INVITATION
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Steno Diabetes Center Copenhagen
Sponsor type: Other
Enrollment: 50
Started: 2025-11-20
Primary completion: 2026-11-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Proteomic feasibility

Conditions studied

Type 2 DM · Type 2 DM /Diabetic Nephropathy · Albuminuria

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.